Sulfiscon SA
ActiveLimited or Corporation721001 - Research and experimental development in the pharmaceutical industry
Biotechnology / Pharmaceutical research and developmentPatients suffering from genetic disorders of pathologic calcification and rare skin disorders of calcification.
Sulfiscon SA is a Swiss AG registered in Pully, VD. Its registered activity falls under Research and experimental development in the pharmaceutical industry.
AI-enriched data· marks AI-enriched fields
AI Insight
Registry narrative generated from SHAB/SOGC facts.
Employees~""Revenue""Officers3Active Relations3Deleted Relations0SOGC Records2First Record17.02.2021Latest Activity09.03.2021BiotechnologyOsteoarthritis treatmentPathological calcificationCHUV spin-offHydrogen sulfide research
Registry Information
- Swiss UID
- CHE-300.231.989
- Legal Name
- Sulfiscon SA
- Legal Form
- Limited
- Incorporated
- 15 Mar 2017
- Share Capital
- 10'000'000 actions nominatives de CHF 0.01, avec restrictions quant à la transmissibilité selon statuts.
- Canton
- VD
- Status
- Active
- Country
- Switzerland
Company Purpose
Translating…
NOGA Codes
(Industry classification)Research and experimental development in the pharmaceutical industry
NPROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES72Scientific research and development721Research and experimental development on natural sciences and engineering7210Research and experimental development on natural sciences and engineering721001
Industry Health
Registered Address
Avenue des Cerisiers 45, 1009 Pully
1009, Pully, VD
Companies at this address
Enrich from integrations
Pull data from your connected providers and merge it with the registry.
Registry Pulse
Registry pulse is a Pro feature
Current Directors & Officers
From the web
Target Customers
Patients suffering from genetic disorders of pathologic calcification and rare skin disorders of calcification.
Sources (7)
Allosteric activators of cystathionine γ lyase to augment endogenous hydrogen sulfide and inhibit pathologic calcification. - Abstract - Europe PMC
europepmc.org
Sulfiscon awarded Innosuisse financing for its breakthrough treatment of osteoarthrisis |
pactt.ch
Sulfiscon SA, Pully | OnlineInfo.ch Firmeninformation
onlineinfo.ch
Developing a gasotransmitter based treatment for pathological skin and tendon calcification | ZHAW Zurich University of Applied Sciences
zhaw.ch
Registre du commerce :: page 2665 :: Feuille des Avis Officiels du canton de Vaud
faovd.ch
Allosteric activators of cystathionine γ lyase to augment endogenous hydrogen sulfide and inhibit pathologic calcification
iris.unina.it
Number 10 - June 2022
wp.unil.ch